Martin Henner Voß
Geboren:
1976
Hat mitgewirkt an:
-
p16-INK4a controls the morphology program associated with cellular senescence
-
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
-
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma